This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): inhaled ciprofloxacin, BAY Q3939, BAYQ3939, Cipro Inhaled
Description: Ciprofloxacin dry powder inhaler (DPI) combines ciprofloxacin dry powder that is formulated using Novartis' Proprietary PulmoSphere technology with an easy-to-use delivery inhaler.
Ciprofloxacin is a broad spectrum oral fluoroquinolone that effects a wide range of gram-negative and gram-positive microorganisms. The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
Deal Structure: In January 2005, Nektar and Bayer signed a collaboration to develop inhaled Ciprofloxacin. Under the terms of the collaboration, Nektar will be responsible for formulation of the dry powder and development of the inhalation system, as well as clinical and commercial manufacturing of the drug formulation and device combination. Bayer will be responsible for the clinical development and worldwide commercializationof the system. Nektar will receive funding for preclinical development, milestone payments, and royalty payments when and if the product is commercialized.
Partners: Nektar Therapeutics Novartis AG
Ciprofloxacin DPI News
Additional information available to subscribers only: